TX-MAVENIR
Mavenir, the Network Software Provider building the future of networks with cloud-native software that runs on any cloud and transforms the way the world connects, today announced multiple Communications Service Providers (CSPs) are upgrading their Business Support System (BSS) with Mavenir’s Digital Enablement Platform (MDE) to offer new digital services that monetize 5G network investments.
MDE is a cloud-native, catalog-driven digital BSS that enables CSPs to easily create new 5G digital offerings or complete the 5G network transformation with charging and mediation functions and can also be used to design a digital marketplace experience, bundling cross-industry partner products and services into unified offerings. “With Mavenir’s MDE platform, CSPs can innovate fearlessly by rapidly introducing new services, and capture their customers’ interest, to become an integral part of their digital life,” said Sandeep Singh, GM Digital Enablement at Mavenir.
MDE can run as a comprehensive BSS or importantly, as a digital overlay with existing legacy BSS for minimal risk and disruption. BSS digital overlay systems can help CSPs to maximize returns in the 5G era. Analysys Mason forecasts, “The digital overlay approach can also reduce costs considerably, potentially saving CSPs up to 50% over 3-5 years when compared with traditional transformation approaches.1 ”
Recent deployment examples of Mavenir’s MDE include:
- A leading CSP in Japan for business-to-business (B2B) mobility services
CSP successfully launched its Mobility Bundle Services targeted toward business customers. The typical service includes a bundle of SIM+Handsets purchased in bulk (10s-1000s). The BSS provided a first-of-its-kind agile, co-development, automated CI/CD enabling quarterly updates including modules like Product Catalog, CRM, CPQ, Order Management, Provisioning, Inventory tracking, Offline Rating & Charging, Billing, Invoicing, Payments and Collections.
Mavenir’s digital BSS, deployed as overlay BSS, is the primary for managing B2B customer account lifecycle and connects back to the existing consumer BSS, to leverage capabilities for Individual SIM activation, Number Portability workflow, Resource Inventory management and Network Mediation.
Deployment is on CSP's private cloud over the Kubernetes-based Containers-as-a-Service (CaaS) and Platform as a service (PaaS) layer.
- Large MVNO in Germany transitioning to MNO deploying MDE converged charging system (CCS) & Charging Gateway Function (CGF) for 4G+5G Converged Charging
Transitioning to becoming an MNO with owned RAN, Core, IT, BSS, and Charging system. The CCS includes the 4G OCS enabling Voice, SMS, Data service rating, and charging on real-time Diameter interfaces by integrating with the EPC and IMS network elements. The same core CCS engine also includes 5G CHF, integrated with Mavenir 5GC (5G Core) NFs. The Charging Gateway Function (CGF), also part of the CCS solution, provides for a modern microservice-based network and billing mediation functionality. While the first set of services, including 5G FWA is expected to go live in 2022, the solution is designed to deliver charging for Voice, Messaging, Data (4G+5G eMBB) and IoT in truly agile CI/CD based updates over the next two years. Deployment is on CSP's private cloud over the Kubernetes-based CaaS and PaaS layer.
- Greenfield CSP in Guyana selects MDE for E2E BSS and Charging
Deploying end-to-end BSS and Charging for their 4G+5G Mobile and Fixed Wireless service rollout. The first phase of this multi-phase enables the CSP to launch Prepaid LTE Voice, Data, and SMS services in 2022, leveraging a 4G OCS (Online Charging System) solution for prepaid voice, data, and messaging charging. The second phase will introduce Postpaid services built on top of the BSS. The final phase includes the launch of the 5G eMBB service that will be deployed using MDE 5G CCS integrated with the other vendor's 5GC.
Supporting material:
Mavenir Digital Enablement (MDE) Solution Brief
MDE Introduction Video
MDE Composable BSS Video
Mavenir’s Charging Gateway Function Solution Brief
Mavenir’s Converged Charging Solution Brief
Mavenir’s Converge Charging System Video
Other MDE resources –
MDE Digital Marketplace Whitepaper
MDE solution For MVNOs & Digital Brands
MDE IoT Business Management Solution Brief
About Mavenir:
Mavenir is building the future of networks and pioneering advanced technology, focusing on the vision of a single, software-based automated network that runs on any cloud. As the industry's only end-to-end, cloud-native network software provider, Mavenir is focused on transforming the way the world connects, accelerating software network transformation for 250+ Communications Service Providers in over 120 countries, which serve more than 50% of the world’s subscribers. www.mavenir.com
1 Analysys Mason/Mavenir White Paper “BSS digital overlay systems can help CSPs to maximize returns in the 5G era ” – June 2022
View source version on businesswire.com: https://www.businesswire.com/news/home/20220711005119/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom